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August 16, 2011:883–7ResElution-I) (3), including more than 7,000 patients, and found
no differences in the rate of stent thrombosis during the first year
(1.2% vs. 1.2%; odds ratio: 1.01; 95% confidence interval: 0.66 to
1.55; p  0.96) (Fig. 1).
Nevertheless, the potential benefits of biodegradable polymers
should be evaluated with longer follow-up. In fact, when we
analyzed only late (1 month) stent thrombosis, a 40% relative
risk reduction in the rate of stent thrombosis, although not
statistically significant, was found in patients allocated to biode-
gradable polymer stents (0.27% vs. 0.45%, respectively; odds ratio:
0.68; 95% confidence interval: 0.32 to 1.48; p  0.33).
We believe that biodegradable polymers will contribute to
improve the long-term safety of drug-eluting stents, but we will
have to wait for evidence from long-term (several years) follow-up
in large randomized trials.
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Reply
We appreciate the comments of Dr. Salinas and colleagues regarding
our paper (1). The safety of new-generation stents is improving. This
may be the result of several factors, one of which may be the use of
“biodegradable” polymers; other factors may also be as important,
including improved antiplatelet therapy, longer duration of antiplate-
let therapy, and improved initial stent placement using high-pressure
balloons or guidance with intravascular ultrasound and/or optical
computed tomography. Of interest, in the authors’ meta-analysis,
there were 43 patients in the biodegradable group and 41 in the
permanent polymer group. The numbers are therefore small, although
any event is often catastrophic for the individual patient. Given the
low incidence of the phenomenon and the changing technology,
larger series and longer follow-up will be needed, although challeng-
ing. At the present time, a randomized trial with stent thrombosis as
the primary end point is unavailable for study.
We also appreciate the comments of Prof. Kounis regarding
Kounis syndrome. There are multiple issues involved in stent throm-
bosis. Some issues relate to the underlying coronary artery disease,
some to the specific stent design, including bare-metal versus drug-
eluting stents, and for drug-eluting stents in particular the specific
polymer and drug or drugs used. In addition, there are issues of
compliance with and response to dual-antiplatelet therapy. Findings
consistent with hypersensitivity have been seen in some autopsy series,
as mentioned by Prof. Kounis, and may play a role. Continuing
ongoing experience with polymer-free designs as well as different
drugs may help resolve some of the issues. Fortunately, the incidence
of this often catastrophic complication is very low; this very fact makes
reaching definitive evidence-based conclusions about preventive strat-
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Doing the Right Thing
I could not agree more with “minding the gap” between performance
measures and the practice of medicine (1). Having been in the
osition of starting a new heart failure (HF) program over the past 4
ears, I have experienced firsthand the push and pull of meeting
easures versus “doing the right thing” for the patient, which
ometimes are in alignment but not always. I recently looked at our
ospital’s data and found that despite steady improvement in adher-
nce to the “all or none bundle” for the 4 hospital discharge measures
or HF, there was no change in 30-day readmission rates over a 5-year
eriod (2). When improvements in outcomes have been shown in
ther studies, the association between measures and outcomes seems
uch more likely related to “other things” that were not captured,
ather than adherence to the current measures per se (with the possible
xception of angiotensin-converting enzyme inhibitors/angiotensin
eceptor blockers for low left ventricular ejection fraction). Some of
hose “other things” could include the handoff at discharge and need
or close follow-up, although elucidating the most important elements
o prevent morbidity and mortality following a hospitalization for HF
as proven to be elusive. A particular pet peeve of mine has always
een the “smoking cessation” measure for HF. This measure not only
as never been shown to benefit patients with HF, but previous work
n my laboratory with chronic activation of nicotinic receptors in HF
ogs might even suggest biologic plausibility for a benefit in HF (3).
n the current age of quality and performance measures, it remains
ost important to “do the right thing” for the patient while the
easures are being met, rather than simply focusing on meeting the
easures. Additionally, there clearly remains a great need to deter-
ine measures that actually are beneficial for individual patients.
Mark E. Dunlap, MD
HF Section, Heart and Vascular Center
etroHealth Medical Center
epartments of Medicine, Physiology, and Biophysics
ase Western Reserve University
500 MetroHealth Drive
leveland, Ohio 44109
-mail: mdunlap@metrohealth.org
doi:10.1016/j.jacc.2011.01.069
EFERENCES
1. Ghali JK, Massie BM, Mann DL, Rich MW. Heart failure guidelines,
performance measures, and the practice of medicine: mind the gap.
J Am Coll Cardiol 2010;56:2077–80.2. Dunlap ME, Greco PJ, Halliday BL, Einstadter D. Lack of correlation
between HF performance measures and 30-day rehospitalization rates
(abstr). J Card Fail 2009;15:283.
3. Bibevski S, Dunlap ME. Prevention of diminished parasympathetic
control of the heart in experimental heart failure. Am J Phys
2004;287:H1780–5.
Reply
We are delighted that Dr. Dunlap shares our views (1), and we
appreciate the emphasis he places on the need for a careful selection
of performance measures. His observation on the lack of correlation
among patients with heart failure between steady improvement in
adherence to performance measures and 30-day readmission rates
over a 5-year period is noteworthy. The recently published data from
the Veterans Affairs Health Care System document a divergence
between 30-day rehospitalization for heart failure and survival among
50,125 patients with first hospitalization for heart failure (2). Over a
-year period, mortality at 30 days decreased, whereas the number of
ehospitalizations for heart failure increased, highlighting the poten-
ial peril of using hospital readmission as a performance measure (3).
We are less concerned, however, about choosing smoking cessation
ounseling as a performance measure. We agree with Dr. Dunlap that
o controlled clinical trial has documented the benefit of such an
pproach in patients with heart failure. On the other hand, smoking
essation is not associated with potential harm. One of our major
oncerns in converting guideline recommendations into performance
easures is the potential for harm that results from exposing a large
opulation of patients with heart failure to pharmacological and
evice therapy without adequate assessment of the risk/benefit ratio
1). No such concern exists for smoking cessation counseling.
An important limiting feature of smoking cessation counseling as a
erformance measure is that it could be “checked” as having been
erformed when no actual intervention was delivered. The drive and
ncentives to achieve high scores on performance measures encourage
fforts that focus on ensuring that documentation of compliance with
moking cessation counseling was recorded, whether or not such coun-
eling was provided.
In conclusion, we are in complete agreement with Dr. Dunlap that
e should “‘do the right thing’ for the patient while the measures are
eing met, rather than simply focusing on meeting the measures.”
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